Semaglutide results at 4 weeks: what the trial data actually shows

What the STEP 1 trial tells us about the four-week window

The largest phase 3 semaglutide weight-management trial, STEP 1, followed 1,961 adults over 68 weeks and is the primary evidence base cited by both NICE and the NHS. Published in the New England Journal of Medicine, it showed roughly 15% average body-weight reduction at 2.4 mg, but that headline figure reflects the full treatment period, not the first four weeks.

At week four, participants were still on the 0.25 mg dose. The trial's weight-loss curves show the steepest decline occurring between approximately weeks 12 and 44, as doses escalated and appetite suppression intensified. That does not mean nothing is happening at week four. Semaglutide acts on GLP-1 receptors in the brain and gut from the first injection, slowing gastric emptying and reducing hunger signals. Many participants reported eating noticeably less within the first two weeks, the scales just tend to catch up later.

The practical implication: a modest or absent number on the scales at four weeks is expected and does not indicate that the medicine is not working. What you may notice instead is a shift in appetite, an earlier sense of fullness, or less interest in snacking. Those signals are early markers that the mechanism is active.

Why four weeks rarely shows the full picture for semaglutide

Semaglutide's licensed maintenance dose for weight management is 2.4 mg weekly, reached after a titration schedule that spans roughly 16 to 20 weeks, four dose steps, each lasting approximately four weeks. At week four you are finishing the very first step. The body is adjusting to the medicine, side effects (most commonly nausea and digestive changes) tend to peak and then ease during this period, and the clinical priority is tolerability rather than rapid loss.

The NHS medicines page for semaglutide is clear that the treatment is designed to work over months alongside dietary changes and increased activity. Expecting the four-week mark to mirror a 68-week trial result sets an unrealistic benchmark and can lead people to abandon treatment prematurely, before the therapeutic doses have even been reached.

A simple habit worth building now: photograph or write down your starting weight and waist measurement, then check again at 8 and 12 weeks rather than weekly. Daily fluctuations of one to two kilograms from fluid and food are normal and can obscure a real trend. For a longer view of how results develop, our page on semaglutide results at 12 weeks covers what the evidence shows once titration is further along.

Side effects are often most noticeable in the first four weeks

The four-week point is also when gastrointestinal side effects are typically at their highest. Nausea, loose stools, burping, and fatigue are the most frequently reported, and they tend to be most pronounced in the first days after each new dose. For most people they ease within a week or two as the body adapts, and they improve further with each dose step.

This is worth knowing because side effects can make the early weeks feel discouraging, particularly if the scales have not moved much yet. They are not a sign that something is wrong; they are a sign the medicine is pharmacologically active. That said, severe or persistent stomach pain that spreads to your back warrants prompt medical attention, as the MHRA has highlighted acute pancreatitis as an infrequent but serious risk with GLP-1 medicines. Report any suspected side effects through the MHRA Yellow Card scheme.

If you are finding the early weeks difficult and want to understand the full timeline of what to expect, our overview of how long Wegovy takes to work sets out the evidence across the whole treatment course.

What to focus on at four weeks instead of the scales

Clinicians generally look at three markers in the early weeks: tolerability (are side effects manageable?), behavioural change (are eating habits shifting?), and adherence (is each weekly injection being taken correctly?). None of these shows up as a number on the scale, but all three predict longer-term outcomes more reliably than early weight loss alone.

Dietary support matters alongside the medicine. Protein adequacy, staying well hydrated, and maintaining some physical activity all help preserve muscle as weight comes off. If you are curious about what typical progress looks like at the six-week point, our page on semaglutide results at six weeks breaks down what the evidence suggests you might reasonably expect by that stage. Your prescriber and the patient information leaflet are the right sources for personalised guidance on this, not generic online advice.

If you are considering semaglutide and want to understand how the full course of treatment is structured, the Wegovy overview covers the licensed options available in the UK. For people wondering about the cost of private treatment, what Wegovy costs privately explains what a legitimate price should include. And if you are ready to find out whether you meet the clinical criteria, you can check your eligibility with our prescribers, the consultation is free, and every assessment is done by a real clinician, not automated software. It is also worth knowing how long a bottle of semaglutide lasts, since understanding your supply helps you plan ahead and avoid any gaps in treatment.